Oxolife, member of CataloniaBio & HealthTech, presented at the 40th ESHRE annual meeting in Amsterdam the research that shows the efficacy of a non-hormonal oral drug that increases the rate of embryo implantation, pregnancy and live birth rates among infertile women who are undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). The findings represent a significant step towards a first therapeutic tool.
The clinical study carried out by Oxolife (OXOART2), conducted across 28 centers in Europe, has evaluated the oral drug OXO-001 that acts directly on the endometrium (internal uterus recovery) to improve embryo implantation and pregnancy rates. After analyzing the data extracted from the study, there was a significant absolute increase of +6.9 points in the birth rate (42.6% for OXO-001 compared to 35.7% for placebo).
“From scientific societies, key opinion leaders, clinicians and patients, we know that an absolute increase of more than 5 percentage points in ongoing pregnancy is considered clinically meaningful. We observed an increase higher than +9, giving renewed hope to patients and the scientific community. We look forward to advancing this promising treatment through the next phases of clinical development.” comments Dra. Agnès Arbat, OXOLIFE’s CEO and CMO.
Dr. Ignasi Canals, OXOLIFE’s CSO, adds: “We are thrilled with the results of this trial, which highlight OXO-001’s potential to become the first therapeutic treatment to increase embryo implantation success, with a non-hormonal drug using a new mechanism of action, acting directly on the endometrium.”
Related news:
Comments